pharmaphorum

NOVEMBER 19, 2023

Lilly to invest $2.5bn for obesity, diabetes drug production Phil.

105

105

Pharmaceutical Technology

NOVEMBER 19, 2023

ADCs continue to demonstrate efficacy across different tumor types, and their use is expected to expand across indications as more suitable target antigens are identified and new and better technologies emerge.

52

52

Med Ed 101

NOVEMBER 19, 2023

Weight loss has been an essential area in which many pharmaceutical companies have made interventions by providing effective medications that can assist patients dealing with obesity. In this article, we will compare the newly approved weight loss medication Zepbound to a diabetes medication called Mounjaro. We will explore the metabolism, pharmacokinetics, similarities, differences, and criteria […] The post Mounjaro Versus Zepbound – Is There A Difference?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

BioPharm

NOVEMBER 19, 2023

Cell and gene therapies offer new opportunities for the development of potentially life-saving treatments for previously incurable diseases. This eBook informs on bioprocess solutions to support novel drug development.

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Commerce

NOVEMBER 19, 2023

CareMetx, a Hub services company that provides high-touch support to drive therapy initiation and adherence, conducted research involving over 100 participants, using both qualitative and quantitative methods. The primary aim was to understand how therapy manufacturers envision the future of Hubs.

40

40

BioPharm

NOVEMBER 19, 2023

Vetting contract fill finish manufacturers is about more than their capacity. Jubilant HollisterStier advises on what to look for in a sterile fill finish partner.

40

40

BioPharm

NOVEMBER 19, 2023

This note demonstrates identification of Infliximab charge variants from intact mass analysis enabled by two-dimensional liquid chromatography

40

40

Pharmaceutical Commerce

NOVEMBER 19, 2023

Among a variety of Hub vendors, what specific qualities distinguish differentiated support for drug manufacturers? To help answer this question, CareMetx conducted in-depth interviews and surveys with senior leadership at top manufacturers.

40

40

BioPharm

NOVEMBER 19, 2023

Webinar Date/Time: Wed, Dec 13, 2023 10:00 AM EST

52

52

Pharmaceutical Commerce

NOVEMBER 19, 2023

Webinar Date/Time: Thu, Dec 14, 2023 11:00 AM EST

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA